Alpha Tau Medical (DRTS) Q4 2025 earnings summary

Executive summary

• Achieved Japanese marketing approval for Alpha DaRT in head and neck cancer, marking first regulatory approval outside Israel.

• Treated first patient in U.S. brain cancer trial and received FDA approval to start a prostate cancer trial.

• Presented positive pancreatic cancer trial data at ASCO GI Symposium, showing promising response and disease control rates.

• Expanded U.S. manufacturing with a new commercial-scale facility in New Hampshire, licensed for radioactive material.

Financial highlights

• R&D expenses rose to $32.1M for 2025, up from $27.0M in 2024, driven by higher compensation, materials, and contractor costs.

• Marketing expenses decreased to $1.9M from $2.3M year-over-year due to lower compensation and travel.

• G&A expenses increased to $8.4M from $6.7M, mainly due to higher compensation and professional fees.

• Net loss widened to $42.6M ($0.53/share) from $31.8M ($0.45/share) year-over-year.

• Cash, cash equivalents, and deposits totaled $76.9M at year-end 2025, up from $62.9M at year-end 2024.

Outlook and guidance

• Targeting completion of patient recruitment in key U.S. trials for skin, pancreatic, and brain cancers in 2026.

• Initial safety readout from the recurrent GBM trial expected in Q2 2026.

• Focused on executing clinical milestones and commercial preparations, including post-market surveillance in Japan.